To include your compound in the COVID-19 Resource Center, submit it here.

Amgen, Allergan report Phase III data for Herceptin biosimilar

Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) said data from a Phase III study showed ABP 980, a biosimilar

Read the full 193 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE